News Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 ‘Metals in Medicine’ Gordon Research ConferenceJune 27, 2024 Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024June 3, 2024 Gaston Capital Announces New AssociateApril 15, 2024 BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024April 5, 2024 Gaston Capital Names Walthall New Managing PartnerApril 1, 2024 Enviro-Master Services Launches Transformative Enviro-Safe AppMarch 7, 2024 Freemotion Fitness and Aktiv Solutions Forge a Transformative Strategic AllianceFebruary 24, 2024 Aktiv Solutions Unveils the Evolutionary SMITH 3D TrainerFebruary 14, 2024 Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024January 22, 2024 Enviro-Master Earns a Spot on the Prestigious Franchise Times Top 400 ListSeptember 29, 2023 Bold Therapeutics Selected as a 2023 Company to Watch by Life Sciences British Columbia (LSBC)September 14, 2023 Aktiv Solutions Acquires Fitspace Design in Latest Expansion MoveSeptember 12, 2023 Load More News
Positive Phase 2 and Mechanism-of-Action Data for BOLD-100 Presented at 2024 ‘Metals in Medicine’ Gordon Research ConferenceJune 27, 2024
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Biliary Tract and Gastric Cancers at ASCO 2024June 3, 2024
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024January 22, 2024
Bold Therapeutics Selected as a 2023 Company to Watch by Life Sciences British Columbia (LSBC)September 14, 2023
